UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 37

Sortiert nach

DNA Methylation Signature Reveals Cell Ontogeny of Renal Cell Carcinomas

Clinical cancer research, 2016-12, Vol.22 (24), p.6236-6246

2016

Volltextzugriff (PDF)

Performing Automatic Identification and Staging of Urothelial Carcinoma in Bladder Cancer Patients Using a Hybrid Deep-Machine Learning Approach

Cancers, 2023-03, Vol.15 (6), p.1673

2023

Volltextzugriff (PDF)

Hypoxia-induced SUMOylation of E3 ligase HAF determines specific activation of HIF2 in clear-cell renal cell carcinoma

Cancer research (Chicago, Ill.), 2015-01, Vol.75 (2), p.316-329

2015

Volltextzugriff (PDF)

SETD2 loss in renal epithelial cells drives epithelial‐to‐mesenchymal transition in a TGF‐β‐independent manner

Molecular oncology, 2024-01, Vol.18 (1), p.44-61

2024

Volltextzugriff (PDF)

Factors Associated with Survival following Radium-223 Treatment for Metastatic Castration- Resistant Prostate Cancer

Clinical genitourinary cancer, 2017-12, Vol.15 (6), p.e969-e975

2017

Volltextzugriff (PDF)

Phase Ib Study of Atezolizumab Plus Interferon-α with or without Bevacizumab in Patients with Metastatic Renal Cell Carcinoma and Other Solid Tumors

Current oncology (Toronto), 2021-12, Vol.28 (6), p.5466-5479

2021

Volltextzugriff (PDF)

Ebselen inhibits QSOX1 enzymatic activity and suppresses invasion of pancreatic and renal cancer cell lines

Oncotarget, 2015-07, Vol.6 (21), p.18418-18428

2015

Volltextzugriff (PDF)

In silico DNA methylation analysis identifies potential prognostic biomarkers in type 2 papillary renal cell carcinoma

Cancer medicine (Malden, MA), 2019-09, Vol.8 (12), p.5760-5768

2019

Volltextzugriff (PDF)

Extensive intratumor regional epigenetic heterogeneity in clear cell renal cell carcinoma targets kidney enhancers and is associated with poor outcome

Clinical epigenetics, 2023-04, Vol.15 (1), p.71-71, Article 71

2023

Volltextzugriff (PDF)

Concordance of PD‐1 and PD‐L1 (B7‐H1) in paired primary and metastatic clear cell renal cell carcinoma

Cancer medicine (Malden, MA), 2020-02, Vol.9 (3), p.1152-1160

2020

Volltextzugriff (PDF)

A Multidisciplinary Biospecimen Bank of Renal Cell Carcinomas Compatible with Discovery Platforms at Mayo Clinic, Scottsdale, Arizona

PloS one, 2015-07, Vol.10 (7), p.e0132831

2015

Volltextzugriff (PDF)

Trends in Renal-Cell Carcinoma Incidence and Mortality in the United States in the Last 2 Decades: A SEER-Based Study

Clinical genitourinary cancer, 2019-02, Vol.17 (1), p.46-57.e5

2019

Volltextzugriff (PDF)

Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized controlled trial

Clinical cancer research, 2015-03, Vol.21 (5), p.1071-1077

2015

Volltextzugriff (PDF)

Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti-PD-1 Therapies in Metastatic Melanoma

Clinical cancer research, 2018-11, Vol.24 (21), p.5250-5260

2018

Volltextzugriff (PDF)

Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma

Clinical cancer research, 2016-05, Vol.22 (10), p.2445-2452

2016

Volltextzugriff (PDF)

Genetic kidney cancer syndromes

Journal of the National Comprehensive Cancer Network, 2014-09, Vol.12 (9), p.1347

2014

Volltextzugriff (PDF)

Macrophage HIF-1α Is an Independent Prognostic Indicator in Kidney Cancer

Clinical cancer research, 2020-09, Vol.26 (18), p.4970-4982

2020

Volltextzugriff (PDF)

PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation

Cancer immunology research, 2015-12, Vol.3 (12), p.1303-1307

2015

Volltextzugriff (PDF)

Assessing the clinical use of clear cell renal cell carcinoma molecular subtypes identified by RNA expression analysis

Urologic oncology, 2015-02, Vol.33 (2), p.68.e17-68.e23

2015

Volltextzugriff (PDF)

Differential impact of tumor suppressor gene (TP53, PTEN, RB1) alterations and treatment outcomes in metastatic, hormone-sensitive prostate cancer

Prostate cancer and prostatic diseases, 2022-09, Vol.25 (3), p.479-483

2022

Volltextzugriff (PDF)

Clinical Results and Biomarker Analyses of Axitinib and TRC105 versus Axitinib Alone in Patients with Advanced or Metastatic Renal Cell Carcinoma (TRAXAR)

The oncologist (Dayton, Ohio), 2021-07, Vol.26 (7), p.560-e1103

2021

Volltextzugriff (PDF)

Molecular characterization of sarcomatoid clear cell renal cell carcinoma unveils new candidate oncogenic drivers

Scientific reports, 2020-01, Vol.10 (1), p.701-701, Article 701

2020

Volltextzugriff (PDF)

Molecular Inhibitor of QSOX1 Suppresses Tumor Growth In Vivo

Molecular cancer therapeutics, 2020-01, Vol.19 (1), p.112-122

2020

Volltextzugriff (PDF)

Germ Cell Tumors with Malignant Somatic Transformation: A Mayo Clinic Experience

Oncology research and treatment, 2019-01, Vol.42 (3), p.95-100

2019

Volltextzugriff (PDF)

Axitinib in the treatment of metastatic renal cell carcinoma

Future oncology (London, England), 2011-11, Vol.7 (11), p.1247-1253

2011

Volltextzugriff (PDF)

1 – 25 von 37

Suche als RSS-Feed

Aktive Filter

ThemaOncology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(34)
Mit Volltextzugriff
(34)

Publikationsform

Artikel
(36)
Bücher
(1)

Sprache

Englisch
(37)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

Science & Technology
(36)
Life Sciences & Biomedicine
(33)
Humans
(28)
Male
(16)
Carcinoma, Renal Cell - Genetics
(14)
Kidney Neoplasms - Genetics
(14)
Female
(13)
Aged
(12)
Kidney Neoplasms - Pathology
(12)
Middle Aged
(12)
Tumors
(10)
Carcinoma, Renal Cell - Drug Therapy
(9)
Kidney Neoplasms - Drug Therapy
(9)
Aged, 80 And Over
(8)
Carcinoma, Renal Cell - Metabolism
(8)
Carcinoma, Renal Cell - Pathology
(8)
Kidney Cancer
(8)
Patients
(8)
Renal Cell Carcinoma
(8)

14 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Clinical Cancer Research
(5)
Clinical Genitourinary Cancer
(4)
Cancer Medicine
(2)
Clinical Epigenetics
(2)
Current Oncology
(2)
Journal Of The National Comprehensive Cancer Network
(2)
Oncotarget
(2)
Plos One
(2)
Bmc Cancer
(1)
Cancer
(1)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

DNA Methylation Signature Reveals Cell Ontogeny of Renal Cell Carcinomas

Performing Automatic Identification and Staging of Urothelial Carcinoma in Bladder Cancer Patients Using a Hybrid Deep-Machine Learning Approach

Hypoxia-induced SUMOylation of E3 ligase HAF determines specific activation of HIF2 in clear-cell renal cell carcinoma

SETD2 loss in renal epithelial cells drives epithelial‐to‐mesenchymal transition in a TGF‐β‐independent manner

Factors Associated with Survival following Radium-223 Treatment for Metastatic Castration- Resistant Prostate Cancer

Phase Ib Study of Atezolizumab Plus Interferon-α with or without Bevacizumab in Patients with Metastatic Renal Cell Carcinoma and Other Solid Tumors

Ebselen inhibits QSOX1 enzymatic activity and suppresses invasion of pancreatic and renal cancer cell lines

In silico DNA methylation analysis identifies potential prognostic biomarkers in type 2 papillary renal cell carcinoma

Extensive intratumor regional epigenetic heterogeneity in clear cell renal cell carcinoma targets kidney enhancers and is associated with poor outcome

Concordance of PD‐1 and PD‐L1 (B7‐H1) in paired primary and metastatic clear cell renal cell carcinoma

A Multidisciplinary Biospecimen Bank of Renal Cell Carcinomas Compatible with Discovery Platforms at Mayo Clinic, Scottsdale, Arizona

Trends in Renal-Cell Carcinoma Incidence and Mortality in the United States in the Last 2 Decades: A SEER-Based Study

Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized controlled trial

Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti-PD-1 Therapies in Metastatic Melanoma

Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma

Genetic kidney cancer syndromes

Macrophage HIF-1α Is an Independent Prognostic Indicator in Kidney Cancer

PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation

Assessing the clinical use of clear cell renal cell carcinoma molecular subtypes identified by RNA expression analysis

Differential impact of tumor suppressor gene (TP53, PTEN, RB1) alterations and treatment outcomes in metastatic, hormone-sensitive prostate cancer

Clinical Results and Biomarker Analyses of Axitinib and TRC105 versus Axitinib Alone in Patients with Advanced or Metastatic Renal Cell Carcinoma (TRAXAR)

Molecular characterization of sarcomatoid clear cell renal cell carcinoma unveils new candidate oncogenic drivers

Molecular Inhibitor of QSOX1 Suppresses Tumor Growth In Vivo

Germ Cell Tumors with Malignant Somatic Transformation: A Mayo Clinic Experience

Axitinib in the treatment of metastatic renal cell carcinoma

Aktive Filter

Suchergebnisse filtern